Health Economics›Waldenstroem macroglobulinemia›Relapsed or refractory randomized data

Relapsed or refractory randomized data

Waldenstroem macroglobulinemia · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib and Rituximab Variant #05	—	R 391 307	56d	—	—	—	—	2
Fludarabine and Rituximab (FR) Variant #06	—	R 117 749	28d	—	—	—	—	—
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	~39.6 mo	—	~44	~R 1 795 506 PFS proxy · indirect	18
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~20.3 mo	—	~4	~R 208 PFS proxy · indirect	2

4 of 4 regimens shown